Phase II Study Comparing RC108 Plus Furmonertinib to Furmonertinib Alone for First-Line Treatment of EGFR-Mutated, MET-Positive Advanced or Recurrent Non-Small Cell Lung Cancer

What this Trial Is About

Researchers are studying the effectiveness and safety of combining RC108 with Furmonertinib compared to Furmonertinib alone for treating patients with a specific type of advanced or recurrent non-small cell lung cancer NSCLC that has both EGFR mutations and MET positivity. This phase II clinical trial aims to better understand how these treatments work together for this condition. The trial involves two groups one receiving RC108 combined with Furmonertinib, and the other receiving Furmonertinib alone. Participants have unresectable locally advanced or recurrent metastatic NSCLC with certain EGFR mutations and MET positivity. Treatment and monitoring occur over several months, with careful evaluation of drug effects and safety. Participants will undergo tests for tumor response, survival rates, and disease control over a period of up to 45 months. Researchers will collect tissue samples, monitor side effects, and assess drug levels and immune responses. The study includes regular check-ins to measure how well the cancer responds and to track any adverse events or reactions.

A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC